Aigen Investment Management’s Intellia Therapeutics NTLA Stock Holding History

Aigen Investment Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-18,283	Closed	-$213K	–	942
2024 Q4	$213K	Buy	+18,283	New	+$285K	0.04%	593
2023 Q4	–	Sell	-17,569	Closed	-$556K	–	985
2023 Q3	$556K	Buy	+17,569	New	+$682K	0.1%	318
2023 Q1	–	Sell	-10,383	Closed	-$362K	–	754
2022 Q4	$362K	Buy	+10,383	New	+$494K	0.05%	328
2022 Q2	–	Sell	-9,233	Closed	-$671K	–	669
2022 Q1	$671K	Buy	+9,233	New	+$782K	0.12%	232
2021 Q2	–	Sell	-5,093	Closed	-$409K	–	651
2021 Q1	$409K	Sell	5,093 -4,119	-45%	-$276K	0.05%	340
2020 Q4	$501K	Buy	+9,212	New	+$335K	0.07%	390
2020 Q3	–	Sell	-89,571	Closed	-$1.88M	–	1029
2020 Q2	$1.88M	Buy	89,571 +51,221	+134%	+$870K	0.24%	107
2020 Q1	$469K	Buy	+38,350	New	+$517K	0.06%	438

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Aigen Investment Management's NTLA Position: Q1 2025 in Review

Aigen Investment Management sold out of Intellia Therapeutics (NTLA) in Q1 2025, closing a stake of 18,283 shares — an estimated $213K sold.

Aigen Investment Management first reported a position in NTLA in Q1 2020 and held it in 8 quarters. The position peaked at $1.88M in Q2 2020. 294 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.

Aigen Investment Management reported no remaining Intellia Therapeutics position as of Q1 2025 after selling out during the quarter.
Aigen Investment Management sold 18,283 Intellia Therapeutics shares in Q1 2025, an estimated $213K.
Aigen Investment Management first reported a position in Intellia Therapeutics in Q1 2020 and held it in 8 quarters.
Aigen Investment Management's Intellia Therapeutics position peaked at $1.88M in Q2 2020.
294 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.

Based on Aigen Investment Management's 13F filing for Q1 2025, filed 12 May 2025.